Amphotericin B (AmpB), one of the most commonly used agents in the treatment of\nsevere fungal infections and life-threatening parasitic diseases such as visceral Leishmaniasis, has a\nnegligible oral bioavailability, primarily due to a low solubility and permeability. To develop an\noral formulation, medium chain triglycerides and nonionic surfactants in a self-nano-emulsifying\ndrug delivery system (SNEDDS) containing AmpB were combined with room temperature ionic\nliquids (RTILs) of imidazolium. The presence of ionic liquids significantly enhanced the solubility of\nAmpB, exhibited a low toxicity and increased the transport of AmpB across Caco-2 cell monolayers.\nThe combination of RTILs with a lipid formulation might be a promising strategy to improve the oral\nbioavailability of AmpB.
Loading....